Literature DB >> 21226427

Risk factors for hospital-acquired pneumonia caused by imipenem-resistant Pseudomonas aeruginosa in an intensive care unit.

G H Furtado1, A C Gales, L B Perdiz, A E Santos, S B Wey, E A Medeiros.   

Abstract

Imipenem-resistant Pseudomonas aeruginosa is a leading cause of hospital-acquired pneumonia. Aiming to determine the risk factors associated for hospital-acquired pneumonia due to imipenem-resistant Pseudomonas aeruginosa, we undertook a retrospective case-case-control study. Patients admitted to a 14-bed medical-surgical intensive care unit from a university-affiliated hospital with hospital-acquired pneumonia caused by imipenem-resistant Pseudomonas aeruginosa strains and by imipenem-susceptible Pseudomonas aeruginosa strains were matched to control patients by time under risk and comorbidities. A total of 58 resistant cases, 47 susceptible cases and 237 controls were evaluated. The risk factors independently associated to hospital-acquired pneumonia caused by imipenem-resistant Pseudomonas aeruginosa were: duration of hospitalisation, Acute Physiological and Chronic Health Evaluation II score, male gender receipt of haemodialysis, receipt of piperacillin-tazobactam and receipt of third-generation cephalosporins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21226427     DOI: 10.1177/0310057X1003800605

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  8 in total

Review 1.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

2.  Development and Assessment of Risk Scores for Carbapenem and Extensive β-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa Infection.

Authors:  Sara Y Tartof; Jennifer L Kuntz; Lie H Chen; Rong Wei; Laura Puzniak; Yun Tian; Theresa M Im; Harpreet S Takhar; Sanjay Merchant; Thomas Lodise
Journal:  JAMA Netw Open       Date:  2018-10-05

Review 3.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

4.  Similar frequencies of Pseudomonas aeruginosa isolates producing KPC and VIM carbapenemases in diverse genetic clones at tertiary-care hospitals in Medellín, Colombia.

Authors:  Johanna M Vanegas; Astrid V Cienfuegos; Ana M Ocampo; Lucelly López; Helena del Corral; Gustavo Roncancio; Patricia Sierra; Lina Echeverri-Toro; Sigifredo Ospina; Natalia Maldonado; Carlos Robledo; Andrea Restrepo; J Natalia Jiménez
Journal:  J Clin Microbiol       Date:  2014-09-10       Impact factor: 5.948

Review 5.  Gram-negative infections in adult intensive care units of latin america and the Caribbean.

Authors:  Carlos M Luna; Eduardo Rodriguez-Noriega; Luis Bavestrello; Manuel Guzmán-Blanco
Journal:  Crit Care Res Pract       Date:  2014-11-27

6.  Tremella polysaccharides inhibit cellular apoptosis and autophagy induced by Pseudomonas aeruginosa lipopolysaccharide in A549 cells through sirtuin 1 activation.

Authors:  Xiaolan Shi; Wenfeng Wei; Ning Wang
Journal:  Oncol Lett       Date:  2018-04-23       Impact factor: 2.967

7.  Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.

Authors:  Gowri Raman; Esther E Avendano; Jeffrey Chan; Sanjay Merchant; Laura Puzniak
Journal:  Antimicrob Resist Infect Control       Date:  2018-07-04       Impact factor: 4.887

8.  Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis.

Authors:  Alfredo Ponce de Leon; Sanjay Merchant; Gowri Raman; Esther Avendano; Jeffrey Chan; Griselda Tepichin Hernandez; Eric Sarpong
Journal:  BMC Infect Dis       Date:  2020-03-27       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.